# OnCo record iec-hs-management (protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/protocols/iec-hs-management/>
  a schema:MedicalGuideline ;
  onco:kind "protocol" ;
  schema:identifier "iec-hs-management" ;
  schema:name "IEC-HS after CAR T-cell therapy: recognition and stepwise treatment"@en ;
  schema:alternateName "IEC-HS"@en, "immune effector cell-associated HLH-like syndrome"@en, "carHLH"@en, "HLH/MAS after CAR T"@en, "macrophage activation syndrome after CAR T"@en, "MAS-L"@en ;
  schema:description "Rarely after CAR T-cell therapy the immune system stays switched on after cytokine release syndrome has settled, and starts damaging the blood, liver and clotting (IEC-HS). It shows as very high ferritin, falling blood counts, low clotting proteins and liver test changes. It is treated with anakinra and steroids, adding other drugs if it worsens, while infection and relapse are ruled out."@en ;
  schema:url <https://onco.cc/protocols/iec-hs-management/> ;
  schema:dateModified "2026-11-11"^^xsd:date ;
  onco:tag "protocol", "cell-therapy", "car-t", "acute-oncology" ;
  onco:related <https://onco.cc/protocols/crs-grading-and-management/>, <https://onco.cc/protocols/icans-grading-and-management/>, <https://onco.cc/protocols/car-t-infection-prevention/> ;
  onco:technologies <https://onco.cc/technologies/car-t/> ;
  onco:drugs <https://onco.cc/drugs/dexamethasone/>, <https://onco.cc/drugs/methylprednisolone/>, <https://onco.cc/drugs/ruxolitinib/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/emapalumab/> ;
  onco:institutions <https://onco.cc/institutions/sitc/> ;
  onco:terms <https://onco.cc/terms/crs/>, <https://onco.cc/terms/cytopenias/> .